119 related articles for article (PubMed ID: 27533851)
1. Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.
Bins S; Lenting A; El Bouazzaoui S; van Doorn L; Oomen-de Hoop E; Eskens FA; van Schaik RH; Mathijssen RH
Pharmacogenomics; 2016 Sep; 17(14):1483-90. PubMed ID: 27533851
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia.
Peer CJ; Sissung TM; Kim A; Jain L; Woo S; Gardner ER; Kirkland CT; Troutman SM; English BC; Richardson ED; Federspiel J; Venzon D; Dahut W; Kohn E; Kummar S; Yarchoan R; Giaccone G; Widemann B; Figg WD
Clin Cancer Res; 2012 Apr; 18(7):2099-107. PubMed ID: 22307138
[TBL] [Abstract][Full Text] [Related]
3. Early sorafenib-induced toxicity is associated with drug exposure and UGTIA9 genetic polymorphism in patients with solid tumors: a preliminary study.
Boudou-Rouquette P; Narjoz C; Golmard JL; Thomas-Schoemann A; Mir O; Taieb F; Durand JP; Coriat R; Dauphin A; Vidal M; Tod M; Loriot MA; Goldwasser F; Blanchet B
PLoS One; 2012; 7(8):e42875. PubMed ID: 22912756
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma.
Tsuchiya N; Narita S; Inoue T; Hasunuma N; Numakura K; Horikawa Y; Satoh S; Notoya T; Fujishima N; Hatakeyama S; Ohyama C; Habuchi T
Anticancer Drugs; 2013 Mar; 24(3):310-4. PubMed ID: 23237922
[TBL] [Abstract][Full Text] [Related]
5. UGT1A1, SLCO1B1, and SLCO1B3 polymorphisms vs. neonatal hyperbilirubinemia: is there an association?
Alencastro de Azevedo L; Reverbel da Silveira T; Carvalho CG; Martins de Castro S; Giugliani R; Matte U
Pediatr Res; 2012 Aug; 72(2):169-73. PubMed ID: 22580719
[TBL] [Abstract][Full Text] [Related]
6. UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib.
Meza-Junco J; Chu QS; Christensen O; Rajagopalan P; Das S; Stefanyschyn R; Sawyer MB
Cancer Chemother Pharmacol; 2009 Dec; 65(1):1-4. PubMed ID: 19672597
[TBL] [Abstract][Full Text] [Related]
7. Prolonged neutropenia after irinotecan-based chemotherapy in a child with polymorphisms of UGT1A1 and SLCO1B1.
Sakaguchi S; Garcia-Bournissen F; Kim R; Schwarz UI; Nathan PC; Ito S
Arch Dis Child; 2009 Dec; 94(12):981-2. PubMed ID: 19608554
[TBL] [Abstract][Full Text] [Related]
8. Combined effects of the UGT1A1 and OATP2 gene polymorphisms as major risk factor for unconjugated hyperbilirubinemia in Indian neonates.
D'Silva S; Colah RB; Ghosh K; Mukherjee MB
Gene; 2014 Aug; 547(1):18-22. PubMed ID: 24865931
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of serum SLCO1B1 levels and genetic variants of SLCO1B1 rs4149056 and rs2306283 in patients with early and exudative age-related macular degeneration.
Liutkeviciene R; Vilkeviciute A; Slavinskaite A; Petrauskaite A; Tatarunas V; Kriauciuniene L
Gene; 2018 Nov; 676():139-145. PubMed ID: 30010042
[TBL] [Abstract][Full Text] [Related]
10. Genetic Polymorphisms of SLCO1B1, CYP2E1 and UGT1A1 and Susceptibility to Anti-Tuberculosis Drug-Induced Hepatotoxicity: A Chinese Population-Based Prospective Case-Control Study.
Sun Q; Liu HP; Zheng RJ; Wang P; Liu ZB; Sha W; Xiao HP
Clin Drug Investig; 2017 Dec; 37(12):1125-1136. PubMed ID: 28900877
[TBL] [Abstract][Full Text] [Related]
11. Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.
Casadei Gardini A; Faloppi L; De Matteis S; Foschi FG; Silvestris N; Tovoli F; Palmieri V; Marisi G; Brunetti O; Vespasiani-Gentilucci U; Perrone G; Valgiusti M; Granato AM; Ercolani G; Negrini G; Tamburini E; Aprile G; Passardi A; Santini D; Cascinu S; Frassineti GL; Scartozzi M
Eur J Cancer; 2017 Nov; 86():106-114. PubMed ID: 28985579
[TBL] [Abstract][Full Text] [Related]
12. A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
Yang H; Woo HY; Lee SK; Han JW; Jang B; Nam HC; Lee HL; Lee SW; Song DS; Song MJ; Oh JS; Chun HJ; Jang JW; Lozada A; Bae SH; Choi JY; Yoon SK
Clin Mol Hepatol; 2017 Jun; 23(2):128-137. PubMed ID: 28494528
[TBL] [Abstract][Full Text] [Related]
13. Genetic link with cholelithiasis among pediatric SCA Tunisian patients: Examples of UGT1A1, SLCO1A2 and SLCO1B1.
Chaouch L; Kalai1 M; Darragi I; Boudrigua I; Chaouachi D; Ammar SB; Mellouli F; Bjaoui M; Abbes S
Hematology; 2016 Mar; 21(2):121-5. PubMed ID: 26146896
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
[TBL] [Abstract][Full Text] [Related]
15. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
16. Outcomes of treatment with sorafenib in Egyptian patients with hepatocellular carcinoma: a retrospective cohort study.
Nada Y; Rashad N; Eissa M; Ghonaim A; Farag K; Saadawi I; Sheha A; El Gewaity M; Abdel-Rahman O
Expert Rev Gastroenterol Hepatol; 2018 Jan; 12(1):99-107. PubMed ID: 29124987
[TBL] [Abstract][Full Text] [Related]
17. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
18. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma.
Lin SM; Lu SN; Chen PT; Jeng LB; Chen SC; Hu CT; Yang SS; Le Berre MA; Liu X; Mitchell DY; Prins K; Grevel J; Peña CA; Meinhardt G
Hepatol Int; 2017 Mar; 11(2):199-208. PubMed ID: 27909950
[TBL] [Abstract][Full Text] [Related]
19. Long-term therapy with sorafenib is associated with pancreatic atrophy.
Xu L; Zhou DS; Zhao J; Spolverato G; Zhang YJ; Li SP; Chen MS; Pawlik TM
J Surg Res; 2015 Dec; 199(2):314-21. PubMed ID: 26115806
[TBL] [Abstract][Full Text] [Related]
20. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E
Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
